title: Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
abstract: In November 2010, the iPrEx study reported that preexposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly scheduled follow-up visits from January to March 2011, participants in an ongoing phase 2b vaccine efficacy trial completed an anonymous Web survey about PrEP. Among 376 respondents, 17% reported they were very likely to use PrEP in the next year. Nonwhite participants were more likely to use PrEP. Among those with some level of interest, intent to use PrEP was greatest if the drug were available through the clinical trial or health insurance. Most (91%) believed taking PrEP would not change their willingness to stay in the vaccine trial and few thought it would affect recruitment. As key stakeholders, currently enrolled trial participants can offer vital input about emerging prevention technologies that may affect the design of future HIV vaccine and nonvaccine prevention trials.
authors.affiliation: San Francisco Department of Public Health, San Francisco, CA 94102, USA. jonathan.fuchs@sfdph.org
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Fuchs
authors.forename: Magdalena E
authors.initials: ME
authors.lastname: Sobieszczyk
authors.forename: Tamra
authors.initials: T
authors.lastname: Madenwald
authors.forename: Doug
authors.initials: D
authors.lastname: Grove
authors.forename: Shelly T
authors.initials: ST
authors.lastname: Karuna
authors.forename: Michele
authors.initials: M
authors.lastname: Andrasik
authors.forename: Adam
authors.initials: A
authors.lastname: Sherwat
authors.forename: Gail
authors.initials: G
authors.lastname: Broder
authors.forename: Kenneth
authors.initials: K
authors.lastname: Mayer
authors.forename: Beryl
authors.initials: B
authors.lastname: Koblin
authors.forename: Scott
authors.initials: S
authors.lastname: Hammer
mesh_terms: D016915:AIDS Vaccines / Q000627:therapeutic use*; D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068679:Emtricitabine; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D020010:Heterosexuality; D018451:Homosexuality, Male; D006801:Humans; D033182:Intention; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D012107:Research Design; D011795:Surveys and Questionnaires; D000068698:Tenofovir; D055815:Young Adult
chemical_list: D016915:AIDS Vaccines; D019380:Anti-HIV Agents; D063065:Organophosphonates; D003841:Deoxycytidine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine